Abiomed Inc (ABMD) Q4 2021 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble.
Abiomed Inc (NASDAQ: ABMD)
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Fourth Quarter 2021 Abiomed Earnings Conference Call. [Operator Instructions]
I would now like to hand the conference over to Todd Trapp. Please go ahead.SPONSORED:
10 stocks we like better than Abiomed
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade,
Motley Fool Stock Advisor, has tripled the market.
iCAD (ICAD) Q1 2021 Earnings Call Transcript
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Markets
In a report released today, Marie Thibault from BTIG reiterated a Buy rating on Accuray (ARAY – Research Report), with a price target of $9.00. The company’s shares closed last Tuesday at $5.32, close to its 52-week high of $6.02.
According to TipRanks.com, Thibault is a 5-star analyst with an average return of 74.2% and a 64.9% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Irhythm Technologies, and Edwards Lifesciences.
Accuray has an analyst consensus of Moderate Buy, with a price target consensus of $8.00.
The company has a one-year high of $6.02 and a one-year low of $1.75. Currently, Accuray has an average volume of 790.2K.
AtriCure Inc (ATRC) Q1 2021 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble.
AtriCure Inc (NASDAQ: ATRC)
Operator
Good afternoon and welcome to AtriCure s First Quarter 2021 Earnings Conference Call. My name is Snell, and I ll be your coordinator for the call today. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session toward the end of today s call. As a reminder, this call is being recorded for replay purposes.
I would now like to turn the call over to Lynn Lewis from the Gilmartin Group for a few introductory comments. Ma am?SPONSORED:
Markets
In a report released yesterday, Marie Thibault from BTIG maintained a Hold rating on Masimo (MASI – Research Report). The company’s shares closed last Monday at $242.67.
According to TipRanks.com, Thibault is a 5-star analyst with an average return of 74.1% and a 61.5% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Edwards Lifesciences, and Irhythm Technologies.
Masimo has an analyst consensus of Moderate Buy, with a price target consensus of $297.50, implying a 20.3% upside from current levels. In a report issued on April 12, Needham also assigned a Hold rating to the stock.
Based on Masimo’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $295 million and net profit of $70.67 million. In comparison, last year the company earned revenue of $248 million and had a net profit of $52.92 million.
vimarsana © 2020. All Rights Reserved.